Pan-specific vaccine to control Streptococcus agalactiae disease in tilapia aquaculture

控制罗非鱼养殖中无乳链球菌病的泛特异性疫苗

• 批准号: 132168
• 金额: $ 32.44万
• 依托单位: MOREDUN RESEARCH INSTITUTE
• 依托单位国家: 英国
• 项目类别: BEIS-Funded Programmes
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132168
• 关键词: Pan; specific; vaccine; control; Streptococcus

As the world population grows and becomes more affluent, an increasing number of people includeprotein in their diet. Aquaculture is the fastest growing source of animal protein and a major source ofincome in Asia, South-America and Africa. Tilapia is a popular fish, both with farmers and consumers,but disease can cause massive losses on tilapia farms. Streptococcus agalactiae, which can affect tilapiaas well as people, is a major cause of such losses. Currently, antibiotics are commonly used to combatthis problem. This is not sustainable because of the risk of antimicrobial resistance. As an alternative, wepropose to develop a vaccine that would protect fish from all types of S. agalactiae that affect them. Thisproject brings together scientific expertise in the area of fish disease and vaccine development andcommercial expertise in vaccine production and distribution. Jointly, the partners aim to provide theglobal aquaculture industry with effective and affordable tools for sustainable disease control.

随着世界人口的增长和富裕，越来越多的人在他们的饮食中加入蛋白质。水产养殖是增长最快的动物蛋白来源，也是亚洲、南美洲和非洲的主要来源。罗非鱼是一种很受农民和消费者欢迎的鱼类，但疾病会给罗非鱼养殖场造成巨大损失。无乳链球菌可以影响罗非鱼和人，是造成这种损失的主要原因。目前，抗生素通常被用来对抗这个问题。这是不可持续的，因为存在抗菌素耐药性的风险。作为替代方案，我们建议开发一种疫苗，以保护鱼类免受所有类型的无乳链球菌的影响。该项目汇集了鱼病和疫苗开发领域的科学专业知识以及疫苗生产和分销领域的商业专业知识。合作伙伴共同致力于为全球水产养殖业提供有效和负担得起的可持续疾病控制工具。